[ACX 2026] Will the US, UK or EU approve a gene editing therapy for a new condition during 2026?
EuropeOne-OffSanté et médecineScience2moisManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleNon 90.2%
Prévisionnistes
29
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 1 heure
En retard6 janv. 26, 22:51 UTC31 déc. 26, 23:59 UTC
Tendances
Marchés Associés
Questions liées pour le contexte, et non une comparaison de contrats équivalents.
When will commercial gene-editing therapy be available?
Manifold MarketsWill a CRISPR-based gene editing therapy for transthyretin (ATTR) amyloidosis be available in the US by 2027?
Manifold MarketsWill GiveWell research gene-editing mosquitoes to eradicate malaria?
Manifold MarketsWhen will there be a confirmation* of an adult human, whose IQ score was improved by 15 by gene-editing?
Manifold MarketsThere will be more children born via artificial wombs than not in first world countries before 2050
Manifold MarketsPreimplantation genetic diagnosis liberalised in Germany before 2027?
Manifold MarketsRègles
(https://www.metaculus.com/questions/embed/41169) Resolves according to Metaculus resolution.
- Metaculus high-level description: This question will resolve as Yes if any of the US FDA, UK MHRA, or the EU Commission authorizes the use or sale of a therapy whose primary mechanism directly editing the patient's genomic DNA for any human condition other than sickle cell disease and beta thalassemia before January 1, 2027.
